北京厚燊维康科技

Beijing Houshen Weikang Technology is a specialized biotechnology firm headquartered in Beijing, China, dedicated to the innovation of exosome-based drug delivery and therapeutic platforms. The company focuses on engineering exosomes to enhance their targeting capabilities and stability, facilitating the delivery of diverse therapeutic agents such as RNA and proteins. Their primary research efforts are directed toward oncology and inflammatory diseases, where traditional delivery methods often face significant challenges. By leveraging advanced bioprocessing and modification techniques, Houshen Weikang aims to translate cutting-edge extracellular vesicle research into effective clinical solutions. The company operates as a private entity, supported by venture capital and academic collaborations within the Chinese life sciences ecosystem.